Director: Jeffrey Supko
Location: 32 Fruit Street, Jackson Building, 10th Floor, Boston
| Core Summary: |
The Cancer Pharmacology Core provides DF/HCC investigators with the necessary expertise and resources to design and undertake pharmacokinetic studies in phase I and phase II clinical trials and preclinical investigations. The Core can implement and validate established analytical methods to quantify drugs and their metabolites in biological fluids; it can also modify or develop entirely new assays when necessary.
| Personnel/Contact Information: |
MGH
Director: Jeffrey Supko, Ph.D.
Phone: (617) 724-1970
Fax: (617) 726-6974
Email: jsupko@partners.org
Other Staff:
Research Associate: Xiaoying He, Ph.D.
Phone: (617) 726-5854
Email: xhe@partners.org
DFCI
Research Associate: Olga Tretyakov, M.D.
Phone: (617) 632-5625
Fax: (617) 632-2933
Email: olga_tretyakov@dfci.harvard.edu
| Facilities: |
Location of Core:
The facility is located at 32 Fruit Street, Jackson Building, 10th Floor, Boston.
| Services: |
►Experimental
design and protocol development
►Preparation
of dosing and sample collection case report forms and sample labels
►Establishing
and implementing appropriate procedures for sample handling, processing,
and storage prior to analysis
►Sample storage
and tracking
►Study oversight
►The development,
validation, and application of analytical methods to measure drugs and
their metabolites in biological fluids
►Metabolite identification
►PK data analysis
and interpretation
►Correlation analyses
to assess the influence of pathophysiologic variables on PK parameters
and associations between PK parameters and biological effects such as toxicity,
biological
correlates, and therapeutic response
►Assistance in the
preparation of manuscripts and presentations
| Fee Schedule/Rates: |
It is not feasible to develop a predetermined cost schedule
for the services offered by the
Core because of the highly specialized and varied nature of bioanalytical methods. The
integrated collection of procedures that comprise an analytical method, which
include sample
storage, preliminary sample preparation, chromatographic analysis, and detection
depend
upon the unique physicochemical characteristics of the particular drug of interest,
the sample
matrix, and nature of the application. Costs for the analysis of samples
depend upon whether
the particular assay has already been established within the facility, whether
suitable assays
for a drug have been described in the literature, or whether an entirely new
assay will need
to be developed. The complexity of the sample preparation and detection
methods used in an
assay also significantly impact costs. Costs for assay development are
largely dependent upon
the physicochemical properties of the compound, as well as its potency, which
generally dictates
the sensitivity required to adequately detect systemic levels of drug afforded
by tolerated doses.
Accordingly, the costs for bioanalytical services must be developed individually for each project.
| Getting Started: |
To access the core, please contact Jeffrey Supko at (617) 724-1970 or by email at
jsupko@partners.org.
| Departmental Web Link: |
http://www.dfhcc.harvard.edu/core-facilities/cancer-pharmacology/
